Cardiac-specific GCN5L1 deficiency promotes MASLD in HFpEF

Area of Science:

• Cardiology
• Metabolic Diseases
• Hepatology

Background:

• Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent.
• Current HFpEF treatments manage comorbidities like obesity, diabetes, and hypertension.
• Existing research explores how liver disease impacts the heart in metabolic syndrome.

Purpose of the Study:

• To investigate the relationship between cardiac metabolism and liver disease in HFpEF.
• To identify novel molecular mechanisms linking HFpEF and metabolic dysfunction-associated liver disease (MASLD).
• To challenge the prevailing view of liver-to-heart disease progression.

Main Methods:

• Analysis of cardiac metabolism in HFpEF models.
• Investigation of the role of the mitochondrial protein GCN5L1.
• Assessment of GCN5L1's impact on liver pathology, including hepatic steatosis and MASLD.

Main Results:

• A defect in cardiac metabolism, specifically involving the mitochondrial protein GCN5L1, was identified in HFpEF.
• This cardiac metabolic defect was found to drive hepatic steatosis and MASLD.
• This study presents the first evidence of a heart-to-liver disease mechanism in HFpEF.

Conclusions:

• Cardiac GCN5L1 deficiency contributes to liver disease development in HFpEF.
• This finding offers a new perspective on the interplay between cardiac and liver metabolic health.
• Targeting cardiac metabolism may offer novel therapeutic strategies for HFpEF and associated MASLD.